Avtor/Urednik		Markovič, Saša; Drozina, Gorazd; Vovk, Marjeta; Fidler-Jenko, Marija
Naslov		Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients
Tip		članek
Vir		Hepatogastroenterology
Vol. in št.		Letnik 46, št. 29
Leto izdaje		1999
Obseg		str. 2925-30
Jezik		eng
Abstrakt		Backgrounds/aims: The aim of this prospective study was to determine the prevalence of hepatitis B (HBV) and hepatitis C viral (HCV) infection as well as to study the morbidity and mortality of viral reactivations in patients treated with corticosteroid containing chemotherapy. Methhodology: From January 1991 to April 1996, 305 patients admitted for treatment of Hodgkin's disease and non-Hodgkin's lymphoma were tested for HBV, and 181 patients for HCV infection. They were followed-up regularly on a monthly basis with liver biochemistry and viral serology. Results: The prevalence of HBs antigen and hepatitis C antibody was found to be 3.2% and 16% respectively. There were 9 reactivations of HBV among 8 HBs antigen positive patients (78%), one among 35 HBs antigen negative patients (2.8%) and none in HCV positive patients. In 83% of cases, reactivation was connected to chemotherapy and corticosteroids. The overall death rate of HBV reactivation was 37%; in severe hepatitis it was 60%. All fatal reactivations were in anti-HBe positive patients. Conclusions: The low prevalence of HCV failed to demonstrate an association between hepatitis C viral infection and lymphoma in Slovenia. Reactivation of HBV infection in HBsAg positive malignant lymphoma patients is a common and often fatal complication of treatment.
Deskriptorji		ADRENAL CORTEX HORMONES HEPATITIS B HEPATITIS B VIRUS HEPATITIS C HEPATITIS C-LIKE VIRUSES HODGKIN'S DISEASE IMMUNOSUPPRESSIVE AGENTS LYMPHOMA LYMPHOMA, B-CELL OPPORTUNISTIC INFECTIONS RISK FACTORS SURVIVAL RATE VIRUS ACTIVATION SLOVENIA